senolytic therapy approval pathway
FDA vs Senolytics - The 2027 Longevity Science Battle
By 2027 the FDA will define the regulatory framework that decides whether senolytics and other longevity therapies can move from research labs to patients, focusing on healthspan endpoints, a new Longevity Review Division, and clear rules for biomarker use. In 2026, the ARDD agenda signals a shift toward longevity regulation,